Mydecine Innovations Group, Inc. (TSE:MYCO) has released an update.
Mydecine Innovations Group Inc. has announced a strategic restructuring to enhance its financial stability, including a private placement of shares at $0.018 each, to be purchased by CEO Josh Bartch, and debt settlements with key insiders. The restructuring aims to streamline the company and bolster its drug development programs, leveraging its considerable intellectual property assets. These initiatives are subject to shareholder approval and are designed to improve the balance sheet and working capital of the company.
For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.
